

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA)	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
2012-13							
Macular oedema (diabetic) - ranibizumab (TA274) Review of TA237	27/02/2013	Ranibizumab - possible treatment for problems with sight due to diabetic macular oedema if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, only as part of an agreed patient access scheme.	x		19/03/2013	20	
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)	27/02/2013	Apixaban - recommended as a option for prevention of stroke and systemic embolism in people with atrial fibrillation and one or more risk factors, but without underlying heart valve disease.	x		19/03/2013	20	To be used in conjunction with SLCSN guideline
Melanoma (BRAF V600 mutation positive, unresectable or metastatic) - vemurafenib (TA269)	12/12/2012	Vemurafenib – recommended for this indication only as part of agreed patient access scheme.	x		12/12/2012	0	LCNDG + CDF recommendation
Melanoma (stage III or IV) - ipilimumab (TA268)	12/12/2012	Ipilimumab – recommended option after prior therapy for advanced melanoma (unresectable or metastatic), only as part of agreed patient access scheme.	x		12/12/2012	0	LCNDG + CDF recommendation
Chronic heart failure - ivabradine (TA267)	30/11/2012	Ivabradine – recommended option for stable chronic heart failure after 4 weeks of optimised standard drugs alone if heart function meets stated parameters. Given with standard drugs, or instead of beta blockers if not tolerated.	x		18/12/2012	18	To be used in conjunction with SLCSN guideline
Cystic fibrosis - mannitol dry powder for inhalation (TA266)	30/11/2012	Mannitol dry powder for inhalation – recommended option for cystic fibrosis if rhDNase or other osmotic drugs are inappropriate, and lung function is rapidly declining.	x		18/12/2012	18	
Bone metastases from solid tumours - denosumab (TA265)	31/10/2012	Denosumab – a recommended option instead of a bisphosphonate for preventing skeletal-related events caused by bone metastases from solid tumours. Not recommended for bone metastases from prostate cancer.	x		18/12/2012	48	
Stroke (acute, ischaemic) - alteplase (TA264)	25/09/2012	Alteplase – a recommended option within 4.5 hours of an acute ischaemic stroke if imaging shows no haemorrhage.	x		25/09/2012	0	ESO and SLCSN guidelines
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)	23/07/2012	Rivaroxaban – a recommended option for treating DVT, and to help prevent a pulmonary embolism or another DVT.	x		18/09/2012	57	

Migraine (chronic) - botulinum toxin type A (TA260)	26/06/2012	Botulinum toxin – a recommended option for preventing headaches in some adults with chronic migraine.	x		17/07/2012	21	
Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259)	20/06/2012	Abiraterone – a recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel.	x		20/06/2012	0	LCNDG + CDF recommendation
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)	15/06/2012	Erlotinib – a recommended first-line option in locally advanced or metastatic non-small-cell lung cancer.	x		17/07/2012	32	
Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)	24/05/2012	Rivaroxaban – a recommended option for atrial fibrillation patients with risk factors.	x		19/06/2012	26	To be used in conjunction with SLCSN guideline
Hepatitis C (genotype 1) - telaprevir (TA252)	14/05/2012	Telaprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous interferon treatments.	x		15/05/2012	1	
Hepatitis C (genotype 1) - boceprevir (TA253)	14/05/2012	Boceprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous treatment.	x		15/05/2012	1	
Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)	27/04/2012	Fingolimod – recommended for patients not responding sufficiently to beta interferon.	x		15/05/2012	18	
Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251)	24/04/2012	For first-line treatment of chronic phase Philadelphia-chromosome-positive CML: Imatinib – recommended as an option. Nilotinib – recommended as an option only under a patient access scheme.	x		24/04/2012	0	LCNDG + CDF recommendation
			15	0			
			% "Yes"	% "N/A"	-	Average implement time (days)	
Adherence statistics for 2012-13			100%	0%		16	